Financial Performance - The company's operating revenue for Q3 2022 was approximately CNY 612.60 million, representing a year-on-year decrease of 2.48%[5]. - The net profit attributable to shareholders for Q3 2022 was a loss of CNY 6.69 million, compared to a profit of CNY 8.58 million in the same period last year, marking a decline of 684.65%[5][7]. - For the first nine months of 2022, the total revenue was CNY 1.76 billion, down 3.48% year-on-year due to the ongoing impact of the pandemic and contract terminations[7]. - Total operating revenue for the first three quarters of 2022 was CNY 1,762,497,864.80, a decrease of 3.46% compared to CNY 1,825,974,014.36 in the same period of 2021[24]. - The company's net profit for the first three quarters of 2022 was impacted by a credit impairment loss of CNY -27,621,805.10, compared to CNY -13,890,700.18 in the previous year[24]. - The net profit for Q3 2022 was CNY 16,478,299.16, a decrease of 19.5% compared to CNY 20,355,739.76 in Q3 2021[25]. - The total profit for Q3 2022 was CNY 27,693,271.83, down from CNY 31,093,128.40 in the same period last year, reflecting a decline of 11.5%[25]. - The operating profit for Q3 2022 was CNY 28,741,567.50, compared to CNY 31,746,879.44 in Q3 2021, indicating a decrease of 9.5%[25]. Assets and Liabilities - The total assets at the end of Q3 2022 were CNY 4.18 billion, a decrease of 2.64% compared to the end of the previous year[6]. - Cash and cash equivalents as of September 30, 2022, were CNY 261,866,405.66, a decrease from CNY 473,549,725.12 at the end of 2021[20]. - Total assets as of September 30, 2022, were CNY 4,180,328,732.37, a decrease from CNY 4,293,573,705.49 at the end of 2021[22]. - Total liabilities decreased to CNY 2,455,822,235.01 from CNY 2,550,662,118.81 at the end of 2021, reflecting a reduction of 3.72%[22]. - The company's equity attributable to shareholders was CNY 1,538,508,098.96 as of September 30, 2022, down from CNY 1,562,078,741.56 at the end of 2021[22]. Cash Flow - The company reported a cash flow from operating activities of CNY 93.99 million for the first nine months of 2022[6]. - The cash flow from operating activities for the first nine months of 2022 was CNY 93,998,800.15, a significant improvement from a negative cash flow of CNY -198,098,122.87 in the same period of 2021[30]. - The total cash inflow from operating activities for the first nine months of 2022 was CNY 1,925,750,719.47, compared to CNY 1,830,535,426.66 in 2021, representing an increase of 5.2%[29]. - The cash flow from investing activities for the first nine months of 2022 was negative at CNY -26,471,555.97, an improvement from CNY -138,015,120.50 in the same period of 2021[30]. - The cash flow from financing activities for Q3 2022 was negative at CNY -285,859,867.03, compared to a positive cash flow of CNY 164,792,623.38 in Q3 2021[30]. Expenses and Provisions - Sales expenses increased by CNY 10.59 million, primarily due to the rise in salaries and benefits for sales personnel related to the new business with Johnson & Johnson[8]. - Financial expenses rose by CNY 10.29 million, attributed to increased financing costs[8]. - The company experienced a significant increase in credit impairment provisions, which rose by 98.85% year-on-year, amounting to an additional CNY 13.73 million[8]. - Research and development expenses decreased by 34.95% due to reduced material input and testing costs[14]. - Research and development expenses for the first three quarters of 2022 were CNY 16,811,524.37, a decrease from CNY 25,843,322.03 in the same period of 2021, indicating a reduction of 34.93%[24]. Revenue Sources - The revenue from the Hubei Provincial Tumor Hospital's contracts decreased by approximately 10.22%, resulting in a loss of CNY 49.32 million[12]. - The revenue from the subsidiary Shandong Selis Medical Technology Co., Ltd. decreased by approximately 76.02%, resulting in a loss of CNY 57.22 million due to contract terminations[12]. - Total revenue for Q3 2022 was 2,578,446.09, a decrease from 3,578,063.73 in the same period last year[13]. Other Financial Metrics - Cash and cash equivalents decreased by 44.70% due to a reduction in bank deposits[13]. - Trade financial assets decreased by 95.33% primarily due to the redemption of wealth management products[13]. - Accounts receivable decreased by 72.53% as a result of reduced receivables[13]. - Prepayments increased by 80.42% due to an increase in advance payments for goods[13]. - Long-term equity investments decreased by 45.82% due to the transfer of some long-term investments to other equity instruments[13]. - The company reported a 263.63% increase in accounts payable due to increased settlements using notes payable[13]. - Investment income decreased by 76.35% primarily due to reduced investment losses[14]. - The company had a total of 19,331 common shareholders at the end of the reporting period[16].
塞力医疗(603716) - 2022 Q3 - 季度财报